Loading...
| A01121 | Pages: NA | Aug 2021 | 7193 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the World Acute Ischemic Stroke Diagnosis And Treatment Market
Request Now !Ischemic stroke is caused by a dysfunction in the supply of blood to the brain due to emboli, thrombus or atherosclerosis occurring in cerebral arteries. According to a World Health Organization (WHO) estimate, around 17 million people die every year due to cardiovascular diseases. Heart attacks and strokes respectively account for the highest number of deaths due to cardiovascular diseases, globally. The statistics of the Centres for Disease Control and Prevention suggest that about 87% of all strokes are ischemic strokes. Stroke is one of the leading cause of long term disability, occurring at a higher rate in the old age population. Moreover, stroke leads to 1 out of every 20 deaths, costing around $34 billion to U.S. annually. Higher rates of mortality associated with strokes highlight an impending need for innovative drugs and diagnostic devices.
The two major factors propelling the growth of the acute ischemic stroke diagnosis and treatment market are; large patient pools and a concerning rise in population at a higher risk of developing stroke in the near future. Rising incidence of diabetes along with heavy tobacco users and an increase in the ageing population are significant factors that determine the market growth. However, the high cost of treatment, lack of transparent reimbursement policies, and limited availability of expertise; are likely to restrict the market growth.
The global ischemic stroke diagnosis and treatment market is segmented on the basis of type and geography. According to type, the market is segmented into, diagnostics and therapeutics. The diagnostic market is further segmented into Computed Tomography Scan (CT scan), Magnetic Resonance Imaging (MRI), Carotid Ultrasound, Cerebral Angiography, Electrocardiography, Echocardiography and Blood tests. The therapeutic market further segments into Tissue Plasminogen Activator Anticoagulant, Antiplatelet and Antihypertensive. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific, and LAMEA.
New Product launches and collaborations are some of the key strategies adopted by leading industry players. In March, 2015, FDA approved WATCHMAN, a left atrial appendage closure device designed to prevent stroke in patients with atrial fibrillation. Silk Road Medical, Inc. has launched an Anti-Stroke Enroute Device, a transcarotid neuroprotection system, designed to access the common carotid artery through a minimally invasive technique. NeuroVive Pharmaceutical AB, entered into collaboration with BBB Therapeutics, for development of the NVP014 drug candidate used in the treatment of ischemic strokes.
The companies profiled in this report include, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Cordis Corporation, Koninklijke Philips N.V., GE Healthcare, Siemens AG, Stryker Corporation, Genentech, Inc. and Merck & Co., Inc.
KEY MARKET BENEFITS:
KEY MARKET SEGMENTS:
The global acute ischemic stroke diagnosis and treatment market is segmented below:
Acute Ischemic Stroke Diagnosis and Treatment Market By Type
Acute Ischemic Stroke Diagnosis and Treatment Market By Geography
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH APPLICATIONOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4.
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4 ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. DIAGNOSTICS
4.2.1. Key market trends, growth factors & opportunities
4.2.2. Market size and forecast, by ype
4.2.2.1. Computed Tomography (CT)
4.2.2.1.1. Market size and forecast
4.2.2.2. Magnetic Resonance Imaging (MRI)
4.2.2.2.1. Market size and forecast
4.2.2.3. Carotid Ultrasound
4.2.2.3.1. Market size and forecast
4.2.2.4. Cerebral Angiography
4.2.2.4.1. Market size and forecast
4.2.2.5. Electrocardiography
4.2.2.5.1. Market size and forecast
4.2.2.6. Echocardiography
4.2.2.6.1. Market size and forecast
4.2.2.7. Others
4.2.2.7.1. Market size and forecast
4.2.3. Market size and forecast , by region
4.2.4. Market analysis, by country
4.3. TREATMENT
4.3.1. Key market trends, growth factors & opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Therapeutics
4.3.2.1.1. Tissue Plasminogen Activator
4.3.2.1.1.1. Market size and forecast
4.3.2.1.2. Anticoagulant
4.3.2.1.2.1. Market size and forecast
4.3.2.1.3. Antiplatelate
4.3.2.1.3.1. Market size and forecast
4.3.2.1.4. Antihypertensive
4.3.2.1.4.1. Market size and forecast
4.3.2.2. Surgery devices
4.3.2.2.1. Market size and forecast
4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country
CHAPTER 5 ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY REGION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. North America market size and forecast, by country
5.2.2.1. U.S. acute ischemic stroke diagnosis and treatment market size and forecast
5.2.2.2. Canada acute ischemic stroke diagnosis and treatment market size and forecast
5.2.2.3. Mexico acute ischemic stroke diagnosis and treatment market size and forecast
5.2.3. North America acute ischemic stroke diagnosis and treatment market, by type
5.3. EUROPE
5.3.1. Key market trends
5.3.2. Europe market size and forecast, by country
5.3.2.1. Germany acute ischemic stroke diagnosis and treatment market size and forecast
5.3.2.2. France acute ischemic stroke diagnosis and treatment market size and forecast
5.3.2.3. UK acute ischemic stroke diagnosis and treatment market size and forecast
5.3.2.4. Italy. acute ischemic stroke diagnosis and treatment market size and forecast
5.3.2.5. Spain acute ischemic stroke diagnosis and treatment market size and forecast
5.3.2.6. Rest of Europe acute ischemic stroke diagnosis and treatment market size and forecast
5.3.3. Europe acute ischemic stroke diagnosis and treatment market, by type
5.4. ASIA-PACIFIC
5.4.1. Key market trends
5.4.2. Asia-Pacific market size and forecast, by country
5.4.2.1. Japan acute ischemic stroke diagnosis and treatment market size and forecast
5.4.2.2. China acute ischemic stroke diagnosis and treatment market size and forecast
5.4.2.3. Australia acute ischemic stroke diagnosis and treatment market size and forecast
5.4.2.4. India. acute ischemic stroke diagnosis and treatment market size and forecast
5.4.2.5. South Korea acute ischemic stroke diagnosis and treatment market size and forecast
5.4.2.6. Rest of Asia-Pacific acute ischemic stroke diagnosis and treatment market size and forecast
5.4.3. Asia-Pacific acute ischemic stroke diagnosis and treatment market, by type
5.5. LAMEA
5.5.1. Key market trends
5.5.2. LAMEA market size and forecast, by country
5.5.2.1. Brazil acute ischemic stroke diagnosis and treatment market size and forecast
5.5.2.2. Saudi Arabia acute ischemic stroke diagnosis and treatment market size and forecast
5.5.2.3. South Africa acute ischemic stroke diagnosis and treatment market size and forecast
5.5.2.4. Rest of LAMEA. acute ischemic stroke diagnosis and treatment market size and forecast
5.5.3. LAMEA acute ischemic stroke diagnosis and treatment market, by type
CHAPTER 6 COMPANY PROFILES
6.1. ABBOTT LABORATORIES
6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments
6.2. MEDTRONIC PLC
6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments
6.3. BOSTON SCIENTIFIC CORPORATION
6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments
6.4. CORDIS CORPORATION
6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments
6.5. KONINKLIJKE PHILIPS N.V.
6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments
6.6. GE HEALTHCARE
6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments
6.7. SIEMENS AG
6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments
6.8. STRYKER CORPORATION
6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments
6.9. GENENTECH, INC.
6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments
6.10. MERCK & CO., INC.
6.10.1. Operating business segments
6.10.2. Business performance
6.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
